Insider trading

Period: 120 months Stock: NKTR + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

338 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

338 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

338 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

338 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
338 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
338 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

338 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
9 Apr 2018
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$4.76M 49,500 at 96.13
42.3%
9 Apr 2018
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$997.76K 9,498 at 105.05
10.6%
6 Apr 2018
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$10.13M 110,500 at 91.69
62.1%
Sold half or more
6 Apr 2018
GREER R SCOTT Director
Sold, plan not stated
$2.77M 30,000 at 92.22
18.7%
6 Apr 2018
CHESS ROBERT Director
Sold, plan not stated 2×
$2.30M 25,000 at 92.14
8.4%
5 Apr 2018
Lingnau Lutz Director
Sold, plan not stated
$3.05M 30,000 at 101.74
52.2%
Sold half or more
5 Apr 2018
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$2.04M 20,000 at 101.75
19.9%
7 Mar 2018
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$10.06M 100,144 at 100.45
37.4%
7 Mar 2018
Sold, plan not stated
$3.64M 37,400 at 97.41
48.0%
6 Mar 2018
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$11.79M 120,000 at 98.29
31.0%
6 Mar 2018
Sold, plan not stated
$260.78K 2,600 at 100.30
6.0%
16 Feb 2018
ROBIN HOWARD W President & CEO
Sold, plan not stated
$1.06M 12,788 at 82.94
5.1%
16 Feb 2018
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$404.66K 4,879 at 82.94
1.2%
16 Feb 2018
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$288.38K 3,477 at 82.94
3.4%
16 Feb 2018
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$238.45K 2,875 at 82.94
3.5%
16 Feb 2018
Thomsen Jillian B. SVP & Chief Accounting Officer
Sold, plan not stated
$211.08K 2,545 at 82.94
3.6%
16 Feb 2018
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$201.21K 2,426 at 82.94
3.5%
22 Jan 2018
ROBIN HOWARD W President & CEO
Sold, plan not stated
$6.32M 83,333 at 75.82
25.0%
2 Jan 2018
Sold, plan not stated
$1.76M 30,000 at 58.66
42.6%
13 Dec 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$4.64M 83,333 at 55.69
30.6%
13 Nov 2017
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$601.08K 15,910 at 37.78
6.4%
8 Nov 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$9.03M 300,000 at 30.09
90.6%
Sold half or more
7 Nov 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$1.94M 75,409 at 25.78
70.8%
Sold half or more
6 Nov 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$522.43K 20,914 at 24.98
40.2%
6 Nov 2017
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$128.28K 5,117 at 25.07
8.1%
1 Nov 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$1.96M 83,334 at 23.57
35.3%
9 Oct 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$2.02M 83,333 at 24.20
35.3%
5 Oct 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$1.09M 43,677 at 24.97
58.4%
Sold half or more
5 Oct 2017
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$189.58K 7,583 at 25.00
11.5%
2 Oct 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$2.93M 120,000 at 24.45
65.4%
Sold half or more
2 Oct 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$1.37M 56,704 at 24.21
57.7%
Sold half or more
29 Sep 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$1.04M 43,296 at 24.04
51.0%
Sold half or more
22 Sep 2017
Lingnau Lutz Director
Sold, plan not stated
$109.85K 5,000 at 21.97
15.4%
22 Sep 2017
Sold, plan not stated
$87.44K 4,000 at 21.86
9.0%
21 Sep 2017
CHESS ROBERT Director
Sold, plan not stated
$139.01K 6,400 at 21.72
2.3%
6 Sep 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$1.79M 83,333 at 21.54
35.3%
16 Aug 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated 2×
$1.77M 91,714 at 19.26
37.6%
16 Aug 2017
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$61.38K 3,177 at 19.32
1.4%
16 Aug 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$61.38K 3,177 at 19.32
4.8%
16 Aug 2017
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$57.11K 2,956 at 19.32
4.8%
16 Aug 2017
Thomsen Jillian B. SVP & Chief Accounting Officer
Sold, plan not stated
$51.16K 2,648 at 19.32
5.0%
16 Aug 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$38.58K 1,997 at 19.32
4.6%
16 Aug 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$32.86K 1,701 at 19.32
5.2%
10 Aug 2017
WHITFIELD ROY A Director
Bought
$628.25K 35,000 at 17.95
35.7%
First buy on file
18 Jul 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$1.16M 54,920 at 21.10
55.8%
Sold half or more
14 Jul 2017
Lingnau Lutz Director
Sold, plan not stated
$622.80K 30,000 at 20.76
56.1%
Sold half or more
12 Jul 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$773.81K 36,691 at 21.09
45.7%
11 Jul 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$176.50K 8,389 at 21.04
16.1%
7 Jun 2017
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$1.96M 101,700 at 19.24
30.9%
16 May 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$163.99K 8,388 at 19.55
5.0%
Showing 251–300 of 338. ← Newer Page 6 of 7 Older →